SearchBar Icon

Dry Eye Syndrome Therapeutics Pipeline to Develop with Maximum Drugs Being Derived from Natural Sources

Published Date:   June 2017

According to a new research report “Dry Eye Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, Dry Eye Syndrome currently exhibits a pipeline with 50 drug candidates.

Explore Report Description at:

Dry Eye Syndrome therapeutics pipeline in 2017

The study analyzed that the dry eye syndrome therapeutics pipeline comprises approximately 50 drug candidates in different stages of development.

Insights on pipeline segments

According to the research findings, most of the drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route.

DuraSite technology platform for Dry Eye Syndrome drug development

InSite Vision (A Sun Pharmaceutical Industries Ltd. company) is using DuraSite technology platform for the development of their drug candidates for the treatment of dry eye syndrome. DuraSite is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix.

Natural Sources are being used for the development of drugs in the Dry Eye Syndrome Therapeutics Pipeline

The research found that various companies use natural sources for the development of dry eye syndrome therapeutics pipeline that includes, but not limited to, MC2 Therapeutics and RegeneRx Biopharmaceuticals, Inc.

Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAll BioPharma Co., Ltd. and others.

Dry Eye Syndrome Therapeutics Pipeline Analysis

  • By Phase
  • By Route of Administration
  • By Molecule Type
  • By Company